Avestar Capital, LLC Immuno Gen, Inc. Transaction History

Avestar Capital, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$2.22 - $3.39 $6,324 - $9,658	-2,849 Closed	0 $0
Q2 2019 Aug 06, 2019	BUY	$1.8 - $3.3 $1,528 - $2,801	849 Added 42.45%	2,849 $1,000
Q1 2019 May 09, 2019	BUY	$2.41 - $5.91 $1,149 - $2,819	477 Added 31.32%	2,000 $1,000
Q4 2018 Jan 25, 2019	BUY	$3.94 - $9.7 $772 - $1,901	196 Added 14.77%	1,523 $1,000
Q3 2018 Oct 23, 2018	BUY	$8.6 - $11.26 $206 - $270	24 Added 1.84%	1,327 $1,000

Q2 2018 Aug 10, 2018	BUY	$9.52 - $12.15 $1,723 - $2,199	181 Added 16.13%	1,303 $1,000
Q1 2018 May 10, 2018	BUY	$6.7 - $12.95 $415 - $802	62 Added 5.85%	1,122 $0
Q4 2017 Feb 14, 2018	BUY	$5.07 - $7.92 $5,374 - $8,395	1,060	1,060 $0

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Avestar Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Avestar Capital, LLC with notifications on news.